With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

(CercleFinance.com) - Moderna a publié sur son site internet une lettre aux actionnaires rédigée par son directeur général, Stéphane Bancel ...

Here are the five things you need to know, including the national day of mourning for Jimmy Carter, California wildfires, Newbury Street rents, and quality goat time ...

Pour 2025, les priorités de Moderna incluent la maximisation de la disponibilité et de la part de marché de ses vaccins ...

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...

In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year ...

"We believe that these results validate our bivalent strategy, which we announced and began pursuing in February 2021," said Stéphane Bancel, Moderna's chief executive. He stressed however that ...

In fact, in a promotional video published in parallel with this recent announcement, Bancel hinted that Moderna has ambitious plans to launch multiple products in the coming years, stating that ...

The latter looks likely, given remarks by Moderna chief executive Stéphane Bancel that the vaccine could get approval as early as 2025. That timeframe suggests the company may be waiting for ...